In previous own work, we were able to show that Fc-engineering of an ICAM-1 antibody isolated from a synthetic human scFv antibody library markedly enhanced the antibody’s anti-myeloma activity in vitro and in vivo most likely by improving the recruitment of immune cells (24). Here, ICAM1 is linked to plasma cell myeloma.